VIVANI MEDICAL INC

Company Overview

Vivani Medical (VANI) is a clinical-stage Healthcare / Biotechnology company developing miniature subdermal drug implants using its NanoPortal™ nanoporous titanium-oxide membrane to deliver ultra long‑acting GLP‑1 peptide therapeutics. Lead human programs include NPM‑115 (high‑dose exenatide, LIBERATE‑1 first‑in‑human enrolled with topline expected mid‑2025), NPM‑119 (exenatide for T2D with IND clearance after a prior CMC hold) and a preclinical semaglutide implant (NPM‑139) targeting annual dosing; a veterinary program (OKV‑119) is partnered with Okava. The firm is pre‑revenue, milestone driven, operates R&D/assembly and a GMP suite in Alameda, CA plus an Australian subsidiary for trials, and had 42 employees at year‑end 2024. Key operational dependencies are CMC/manufacturing scale‑up, regulatory approvals for combination drug‑device products, third‑party suppliers, reimbursement, and successful financings or partnerships to fund development.

Executive Compensation Practices

As a small, pre‑commercial biotech in the Medical Equipment/Electromedical industry, Vivani’s executive pay mix is likely skewed toward equity and stock‑based awards with modest cash salaries to conserve cash, consistent with management disclosure that stock‑based compensation valuation is a critical accounting judgment. Performance metrics driving incentive design will be clinical and regulatory milestones (IND clearances, LIBERATE‑1 topline, enrollment milestones, spin‑off execution, and partnering/commercialization deals) rather than near‑term revenue or EBITDA. Recent reductions in G&A and R&D variances (R&D $15.7M in 2024, operating cash burn ~$20.8M in 2024; cash fell to $8.1M by 6/30/2025) increase the likelihood of equity‑linked compensation, milestone‑vesting options/RSUs, and retention bonuses to limit turnover during a cash‑constrained runway. Any completed spin‑off of Cortigent or participation in financings (registered direct offering, private placements) can materially affect realized compensation value and dilution for executives.

Insider Trading Considerations

Insiders have participated in financings (March 2024 registered direct offering net ~$13.7M and a $5.0M private sale to a director in Nov‑2024; post‑period private commitments and a $75M shelf with Jefferies exist), so expect a mix of Form 4 activity reflecting private placements, exercise‑related sales, and occasional market sales tied to liquidity needs. Trading is likely to cluster around discrete binary catalysts (IND clearances, top‑line LIBERATE‑1 results, regulatory interactions on combination drug‑device classification, and spin‑off announcements) — events that can sharply move a thin float and make insider trades highly informative. Regulatory considerations (FDA CDER jurisdiction, material CMC/regulatory updates) will create routine blackout windows and heighten risk of selective disclosure concerns; check Section 16 filings, 10b5‑1 plan disclosures and any lock‑up/restricted‑share terms when assessing insider transactions.